Ab interno canaloplasty (ABiC): description of a novel minimally invasive glaucoma procedure used to treat open-angle glaucoma with 12 month data review

Session Details

Session Title: Glaucoma II

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 10:12

Venue: Hall C4

First Author: : M.Gallardo USA

Co Author(s): :                        

Abstract Details

Purpose:

To investigate the safety and efficacy of ABiC, a novel minimally invasive glaucoma surgery (MIGS), in reducing intraocular pressure (IOP) and glaucoma medication dependence.

Setting:

El Paso Eye Surgeons, P.A., El Paso, Texas, United States of America.

Methods:

This non-randomized single-center case series explored the effect of ABiC as a stand-alone procedure or combined with cataract surgery in adult OAG patients over a 12-month period. Primary endpoints included mean IOP and mean number of glaucoma medications. Secondary endpoints included surgical and postsurgical complications and secondary interventions.

Results:

The study cohort consisted of 122 patients with a baseline mean IOP of 18.6 ± 6.4 mm Hg and mean medication burden of 2 ± 1 drops. At 12 months, IOP reduced to 12.9 ± 2.0mm Hg (n=28) and medications dropped to 1 ± 1--reductions of 30.64% and 50% respectively. Of the 60 patients who underwent stand-alone ABiC, mean IOP was reduced by 37.55% from 21.3 ±7.4 mm Hg preoperatively to 13.3 ± 2.3 mm Hg at 12 months postoperative (n=6) with a 66.66% reduction in medication use. Intra- and postoperative complications were low, with no serious adverse events recorded.

Conclusions:

These data demonstrate that ABiC provides a safe and effective means of managing mild-to-moderate OAG, and that it is effective with or without cataract surgery. ABiC meets the needs of both controlled glaucoma patients by reducing their medication burden, as well as uncontrolled glaucoma patients by reducing IOP.

Financial Disclosure:

NONE